FIELD GUIDE for staff at the central, intermediate and peripheral level
Le présent document donne des indications supplémentaires pour un usage responsable et prudent des
antimicrobiens chez les animaux élevés pour l’alimentation humaine. II convient de le lire en conjonction
avec le Code d’usages international recommandé pour le contrôle de l'utilisation de...s médicaments
vétérinaires (CAC/RCP 38-1993). Les objectifs visés sont la réduction au minimum de l'incidence
potentiellement défavorable sur la santé publique de l'usage d'agents antimicrobiens chez les animaux
élevés pour l’alimentation humaine et, en particulier, du développement d'une résistance aux antimicrobiens. II importe également d'assurer l'usage sûr et utile des médicaments vétérinaires antimicrobiens en médecine vétérinaire en en maintenant l'efficacité
more
Zambia has recognised the Public Health threat of antimicrobial resistance and its impact on morbidity and mortality, as well as the subsequent economic consequences. The country has recorded microorganisms which have developed resistance to antimicrobial drugs. Notable among these are; Multidrug Re...sistant Mycobacterium Tuberculosis (MDR), Human Immunodeficiency virus resistant to antiretroviral drugs, Plasmodium resistance to antimalarial drugs, and fungal species showing indications of resistance to antifungal drugs. Emergence of “Superbugs” such as Methicillin Resistant Staphylococcus aureus (MRSA), Extended Spectrum beta-lactam (ESBL) producing Klebsiella pneumoniae and Vancomycin Resistant Enterococci (VRE) have also been reported.
more
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...COVERY and REMAP-CAP randomised controlled trials triggered this guideline update, resulting in a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19.
Prior recommendations: (a) A recommendation not to use ivermectin in patients with covid-19, regardless of disease severity, except in the context of a clinical trial; (b) a strong recommendation against the use of hydroxychloroquine in patients with covid-19, regardless of disease severity; (c) a strong recommendation against the use of lopinavir-ritonavir in patients with covid-19, regardless of disease severity; (d) a strong recommendation for systemic corticosteroids in patients with severe and critical covid-19; (e) a conditional recommendation against systemic corticosteroids in patients with non-severe covid-19; and (f) a conditional recommendation against remdesivir in hospitalised patients with covid-19.
more
Les activités menées au cours de l'année 2022 ont été effectuées dans le cadre de la mise en œuvre de la stratégie de coopération OMS -Burundi 2019 – 2023 et en accord avec les quatre axes stratégiques qui soustendent le Budget-Programme 2022-2023.
Ce Budget-Programme (BP) est issu du 1...3ème Programme Général de Travail (PGT) de l’OMS (2019-
2024).
more
The document contains a set of indicators that can be used for monitoring traditional and complementary medicine (T&CM) systems in a country.
The core indicator set consists of 16 indicators that were considered essential and collectively able to provide information on T&CM inputs, processes and ou...tputs. A longer list of reference indicators is also available for countries that wish to monitor more indicators or that want to consider alternative metrics that would better suit each country’s T&CM situation, priorities and monitoring capacities.
Each core and reference indicator is accompanied by a set of metadata. This provides information on the indicator rationale, definitions, data elements (numerator, denominator and data disaggregation), frequency of measurement, and data sources. It is a guide towards more standardized data measurement as well as data interpretation.
more
This updated glossary for malaria aims to improve communication and mutual understanding within the scientific community, as well as with funding agencies, public health officials responsible for malaria programmes, and policy-makers in malaria-endemic countries
WHO Guideline. Since 2010, countries in the meningitis belt have started to introduce a new serogroup A meningococcal conjugate vaccine conferring individual protection and herd immunity. Following the successful roll-out of this vaccine, epidemics due to Neisseria meningitidis serogroup A (NmA) are... disappearing, but other serogroups (e.g. NmW, NmX and NmC) still cause epidemics, albeit at a lower frequency and of a smaller size. Due to these changes, WHO organized the review of the evidence to provide recommendations for epidemic control, related to operational thresholds for investigation and response to outbreaks, the use of rapid diagnostic tests, antibiotic regimens in epidemics, and prophylaxis for household contacts of cases
more
SITUATION ANALYSIS AND RECOMMENDATIONS
Lymphatic filariasis is a vector-borne neglected tropical disease that causes damage of the lymphatic system and can lead to lymphoedema (elephantiasis) and hydrocele in infected individuals. The global baseline estimate of persons affected by lymphatic filariasis is 25 million men with hydrocele an...d over 15 million people with lymphoedema. At least 36 million persons remain with these chronic disease manifestations. The disease is endemic in 72 countries. In 2016, an estimated total population of 856 million were living in areas with ongoing transmission of the causative filarial parasites and requiring mass drug administration (MDA). Lymphatic filariasis disfigures and disables, and often leads to stigmatization and poverty. Hundreds of millions of dollars are lost annually due to reduced productivity of affected patients. WHO has ranked the disease as one of the world’s leading causes of permanent and long-term disability.
more
La troisième génération de la Stratégie de Coopération de l’OMS avec les Pays (SCP) concrétise le programme majeur de réforme adopté par l’Assemblée mondiale de la Santé pour renforcer la capacité de l’OMS et faire en sorte que ses prestations répondent mieux aux besoins du pays. E...lle reflète le douzième programme général de travail de l’OMS au niveau du pays, vise à assurer une pertinence accrue de la coopération technique de l’OMS avec les États Membres. Elle met l’accent sur l’identification des priorités et des mesures d’efficience pour la mise en œuvre des réformes de l’OMS et de l’agenda de transformation régional. L’agenda de transformation vise à faire de l’organisation sanitaire régionale une institution clairvoyante, proactive, capable de répondre aux attentes, axée sur les résultats, transparente et responsable. Cette génération de SCP tient compte du rôle des différents partenaires, y compris les acteurs non étatiques, dans la fourniture d’un appui aux gouvernements et aux communautés.
more
The report aims to capture lessons from the COVID-19 pandemic and to highlight the opportunity for more ambitious global action: expanding sustainable access to vaccines for all towards the Immunization Agenda 2030 and pandemic prevention, preparedness and response efforts. The report is organized i...n two sections: the first section provides WHO insights on global vaccine market dynamics, drawing from data provided by Member States, which are, in turn, analysed and displayed in the second section.
more